|Title:||Anti-thrombotic agents derived from snake venom proteins||Authors:||TUR-FU HUANG
|Keywords:||Angiogenesis; Antithrombotic agent; Arterial thrombosis; Disintegrins; Septic inflammation; Snake venom proteins||Issue Date:||2016||Journal Volume:||14||Start page/Pages:||18||Source:||Thrombosis Journal||Abstract:||
Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPIb, α2β1, GPVI, CLEC-2 and integrins αIIbβ3, αvβ3, α5β1 expressed on platelets, endothelial cells, phagocytes, tumor cells, thus affecting cell-matrices and cell-cell interactions. Here, we focus on disintegrins, a class of low molecular mass Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing, cysteine-rich polypeptide derived from various viper snake venoms. This review describes the potential applications of disintegrins in field of integrin-related diseases, especially arterial thrombosis, angiogenesis, tumor progression and septic inflammation. In addition, a novel RGD-containing disintegrin TMV-7 is being developed as a safer antithrombotic agent with minimal side effects, such as thrombocytopenia and bleeding. ? 2016 The Author(s).
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/564108||ISSN:||14779560||DOI:||10.1186/s12959-016-0113-1||SDG/Keyword:||alphaIIb beta3 integrin; angiogenesis inhibitor; anticoagulant agent; antiinflammatory agent; antineoplastic agent; cilengitide; contortrostatin; disintegrin; eptifibatide; integrin; isotretinoin; rhodostomin; snake venom; tirofiban; tmv 7; trigramin; unclassified drug; very late activation antigen 2; very late activation antigen 5; very late activation antigen 6; vidapin; vimocin; angiogenesis; antigenicity; artery thrombosis; drug half life; drug potency; glioblastoma; hemostasis; human; non small cell lung cancer; Review; sepsis; structure activity relation; tumor growth
|Appears in Collections:||藥理學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.